Mark T. Dunbar Disclosures. Hot Topics in Retina. The Challenge. Where is the Fluid? 4/12/2016
|
|
- Cuthbert Francis
- 5 years ago
- Views:
Transcription
1 A PANEL DISCUSSION: RAPID-FIRE POSTERIOR SEGMENT UPDATE! Steve Ferrucci, OD Chief, Optometry Sepulveda VA Plummer St #112e Sepulveda CA, Mark T. Dunbar, OD Bascom Palmer Eye Institute Miami, FL Mark T. Dunbar Disclosures Mark T. Dunbar, OD is on the Advisory Boards for Carl Zeiss Meditec, Allergan, Regeneron, Reed exhibitions. I have received honorarium from some but not all of these companies I do not own stock in any of the companies/technologies discussed today Please silence all mobile devices Hot Topics in Retina OCT Angiography (OCT-A) Has OCT emerged as standard of care? Are all VEGF drugs created equal? Protocol T DRCR.net are we seeing a paradigm shift in the treatment of diabetic retinopathy? Protocol S Are we doing harm to our patients by prescribing AREDS supplements? Evolving treatments of dry AMD The Challenge Being able to correlate what you are seeing clinicallywith what is happening anatomically and then making the correct diagnosis Is there fluid or retinal thickening? Where is the fluid? Being able to diagnose conditions that may not be seen with traditional ophthalmoscopy Where is the Fluid? 1
2 42 y/o Hispanic Female: Burred Vision LE PED involving fovea Advances in Diagnostic Technology can Help Establish a Diagnosis AngioPlex Color Depth Map Normal Eye CNV Color Depth Map combines superficial, deepand avascularmaps and allows for depth visualization of blood flow Superficial Retina Deep Retina Avascular Retina Color Depth Retina Map AngioPlex Maps are flattened 2D representations vasculature. Color Represents Depth in Tissue 2
3 Angiography Analysis : Angiography 3x3 mm AngioPlex - Retina Depth Encoded Structure - Retina OD OS Ischemia near the FAZ Slice: 164 Tracked during scan Macula Angio Scan Angiography Analysis : Angiography 3x3 mm OD OS AngioPlex - Retina Structure - Retina OCT Imaging in Eye Care Has it evolved to be considered Standard of Care? MD vs. OD SDOCT Does it matter which one? Don t be intimidated by the technology Diabetes and Retinal Vascular Disease They want to give me a great deal on a Stratus? 3
4 The ABC s of DME DRCR.net Protocol I Protocol T RISE RIDE READ VISTA VIVID Are All Anti-VEGF Drugs Created Equal? Avastin (Bevacizumab) Lucentis (ranibizumab) Eylea(Aflibercept) Upregulation of VEGF-A 1-39 The Diabetic Retinopathy Clinical Research Network Protocol T Comparative Effectiveness Study of Aflibercept, Bevacizumab and Ranibizumab for DME 22 *Controls in these studies included patients with cataract, macular hole, or epiretinalmembrane in the absence of any retinal vascular disease. DRCR.net: Protocol T At 1 yr Aflibercept(Eylea) group gained 13.3 letters, Ranibiumab(Lucentis) group gained 11.2 letters Bevacizumab(Avastin) group gained 9.7 letters There were no statistically significant differences among subgroups of patients starting the trial with visual acuity between 20/32 and 20/40 Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumabfor diabetic macular edema [published online ahead of print February 18, 2015]. N EnglJ Med. doi: /nejmoa
5 Mean Change in Visual Acuity Letter Score Mean Change in Visual Acuity Letter Score, Full Cohort Week Treatment Group Comparison*: Aflibercept vs. Bevacizumab P<0.001 Afliberceptvs. RanibizumabP= Ranibizumab vs. Bevacizumab P = Weeks DRCR.net If VA was 20/50 or worse Afliberceptgained 18.9 letter Ranibizumab gained 14.2 letters Bevacizumabgained 11.8 letters Aflibercept Bevacizumab Ranibizumab * P-values adjusted for baseline visual acuity and multiple comparisons Mean Change in Visual Acuity Letter Score Mean Change in Visual Acuity Letter Score Baseline Visual Acuity 20/50 or Worse ~ 50% of Cohort 1-Year Treatment Group Comparison*: Aflibercept vs. Bevacizumab P<0.001 Aflibercept vs. Ranibizumab P = Ranibizumab vs. Bevacizumab P = Weeks Aflibercept Bevacizumab Ranibizumab * P-values adjusted for baseline visual acuity and multiple comparisons Mean Change in Visual Acuity Letter Score Mean Change in Visual Acuity Letter Score Baseline Visual Acuity 20/32 to 20/40 ~50% of Cohort Weeks Aflibercept Bevacizumab Ranibizumab ~+8 Mean Change in Visual Acuity Letter Score Mean Change in Visual Acuity Over 2 Years Full Cohort Week Treatment Group Comparison*: Aflibercept vs. Bevacizumab P = 0.02 Aflibercept vs. Ranibizumab P= 0.47 Ranibizumab vs. Bevacizumab P = Weeks Aflibercept Bevacizumab Ranibizumab Mean Change in Visual Acuity Letter Score Mean Change in Visual Acuity Over 2 Years Baseline Visual Acuity 20/50 or Worse ~50% of Cohort Week Treatment Group Comparison*: Aflibercept vs. Bevacizumab P = 0.02 Aflibercept vs. Ranibizumab P= 0.18 Ranibizumab vs. Bevacizumab P = * P-values adjusted for baseline visual acuity and multiple comparisons Weeks Aflibercept Bevacizumab Ranibizumab * P-values adjusted for baseline visual acuity and multiple comparisons 5
6 1 st Exam: 7/22 Are We Seeing A Paradigm Shift in the Treatment of Diabetic Retinopathy? 5 ½ yrs after Initial exam 20/20 OU DRCR.net: Protocol S Is Lucentisas good (noninferior) as traditional PRP for patients with PDR? 55 U.S. clinical sites 203eyes were randomly assigned to receive PRP (completed in 1 to 3 visits) and 191 eyes received 0.5 mg intravitreousranibizumabat baseline and as frequently as every 4 weeks (based on a structured re-treatment protocol) Primary endpoint: mean change in VA letter score from baseline to 2 years. JAMA. 2015; 314(20): doi: /jama (Published). DRCR.net: Protocol S At 2 years, VA improved by 2.8 letters from baseline in the ranibizumabgroup vs. improvement of 0.2 letters from baseline in the PRP group There was more peripheral VF loss and more vitrectomy s in the PRP group vs. Lucentis VF Loss: 213 db in the ranibizumabgroup vs. 531 db in the PRP group PPV: 15% with PRP vs. 4% with Lucentis When DME present, Lucentisdid a better job treating Macular Edema JAMA. 2015; 314(20): doi: /jama (Published). 6
7 Prevalence of DME in the US Approximately 8 million (21%) of people with diabetes have DR million are diagnosed million have DME 3 8.0MM 1 DME in the US Nearly 800,000 Americans suffer from DME but remain undiagnosed 1 Another 1.1 million are diagnosed with DME but are not receiving treatment 1,2 5.8MM MM 1 800K Undiagnosed 1 2.3MM 3 1.5MM 3 1.5MM Diagnosed 1 ~1.1MM Diagnosed, Untreated 1,2 400K 4 240K 4 ~400K Treated 2 DR Prevalence DR Diagnosed DME Prevalence DME Diagnosed DME Treated DME Anti-VEGF Treated 1. NHANES , projected to 2012 US population. 2. Centers for Disease Control and Prevention. June 9, 2014.Saaddine JB, et al. Arch Ophthalmol. 2008;126(12): BioTrends Research Group. TreatmentTrends : Diabetic Retinopathy/Diabetic Macular Edema (US) Proprietary Quantitative Market Research (n=103 retina specialists, n=23,994 DME eyes with central involvement); fielded November Prevalence Diagnosis Rate Treatment Rate 1.BioTrends Research Group. TreatmentTrends : Diabetic Retinopathy/Diabetic Macular Edema (US) Proprietary Quantitative Market Research (n=103 retina specialists, n=23,994 DME eyes with central involvement); fielded November Are We Harming Our Patients By Prescribing Nutritional Supplements in AMD? Macular Degeneration Association 7
8 Is there a conflict of interest between the NEI and B&L? Independent Group Analyzed AREDS Data Estimated Probability 40% 30% Rates to Advanced AMD AMD Categories 3 and 4 by Treatment Group Placebo Antioxidants Zinc Antioxidants + Zinc 28% AREDS2 Inclusion Criteria Bilateral Large Drusen or Late AMD in One Eye 20% 20% 10% 0% 0 25% Risk Reduction P vs. A+Z p<0.01 P vs. Z p< Years Large Drusen GA NV AMD Study Design NOT Really A Control Control 1012 No AREDS 19 Lutein and Zeaxanthin 1044 Randomized Participants n=4203 AREDS 3036 DHA and EPA 1068 AREDS 1148 Lutein/Zeaxanthin + DHA/EPA 1079 The Age-Related Eye Disease Study 2 (AREDS2) Research Group Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age- Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial Published online May 5, 2013 AREDS 659 AREDS minus ß-Carotene 863 AREDS + Low Zinc 689 AREDS minus ß-Carotene + Low Zinc 825 Available at jamanetwork.com 8
9 Estimated Probability 40% 30% 20% 10% 0% 0 Probability of Progression to AAMD Placebo - AREDS L/Z DHA/EPA L/Z & DHA/EPA 31% 31% 30% 29% Years The Answer: AREDS 2 The data did not demonstrate a significant reduction in progression to advanced AMD in any of the three treatment arms as compared to the control group So ARED 1 supplement just as good as AREDS 2 But AREDS2 Formulation Vitamin C (500 mg) Vitamin E (400 IU) Beta Carotene (15 mg) Lutein (10 mg)/zeaxanthin (2 mg) Zinc (80 mg zinc oxide) Copper (2 mg cupric oxide) Omega-3 fatty acids (DHA/EPA) Genetic Testing in AMD Macula Risk (Atic Dx) Retnagene Purchased by Nicox: Relaunched in June 2014 Nicox purchased by Valeant Key Genes Involved in the Development of AMD Clinical Assessment + Genetics LIPC COL8A1 TIMP3 ARMS2 APOE CETP ABCA1 C3 C2 CFB CFI CFH CFH CFI CFB C2 C3 ARMS2 TIMP3 COL8A1 LIPC APOE CETP ABCA1 Complement Oxygen Metabolism Extracellular Matrix Cholesterol Metabolism Smoking BMI Age AMD status Complete set of Risk factors Non-Genetic Factors 40% Genetic Factors 60% 1. CFH 2. CFI 3. C2 4. CFB 5. C3 6. ARMS2 7. TIMP3* 8. COL8A1* 9. LIPC* 10. CETP* 11. ABCA1* 12. APOE 9
10 What is the Relationship between Genetics, AMD and AREDS Supplement? Genetic analysis of 995 patients with intermediate (moderate) AMD who were in the original AREDS 1 study Followed for 12 years Evaluated the interaction of genetics and type of nutritional supplement on progression from moderate to advanced AMD 49% derive more benefit from treatment other than AREDS Patients with genetically determined CFH high risk alleles, zinc was associated with increased progression to advanced AMD Patients with ARMS2 high risk alleles, zinc was associated with DECREASED progression to advanced AMD antioxidants worsened the outcome Patients with CFH risk alleles benefit from antioxidants without zinc but patients with ARMS2 risk alleles benefit from zinc without antioxidant Genetic Testing and Recommending Nutritional Supplements Of the estimated 15 million Americans taking the AREDS formula, more than ten million should not be on either zinc or antioxidants Only about 23% of patients taking AREDS formula should be while the vast majority should not Genotype-directed therapy of the study population would have more than doubled the reduction in AMD progression rate compared to treatment with the AREDS formulation 10
11 June 26, 2014 Epub Sept 4, 2014 Wait - But that s Not All This Week Treatment Responses to Antioxidants and Zinc based on Genetic Profiles Conclusions: The benefit of the AREDS formulation seems the result of a favorable response by patients in only 1 genotype group, balanced by neutral or unfavorable responses in 3 genotype groups 11
12 Heterogeneous response to zinc/antioxidants within AREDS Category 3 patients Take Home Message Genotype Group Better Average -> Worse American Academy of Ophthalmology Avoid routine genetic testing for genetically complex disorders like age-related maculardegeneration until specific treatment or surveillance strategies have been shown in one or more published clinical trials to be of benefit to individuals with specific disease-associated genotypes. In the meantime, ophthalmologists should confine the genotyping of such patients to research studies. 12
13 So Now What? Should we even do Genetic Testing? I think the value is in assessing risk and determing appropriate follow up 61 y/o White Male CC of new onset flashes followed by a central floater RE X 3-4 days Seen by OD 20/30 Dilates with Neo 2.5%, examines with BIO and takes optos photo Diagnosis vitreous syneresis No tobacco dust or Schaeffer s sign Explains Si/Sx of RD Asked to return in 1 mo 61 y/o White Male The pt returns 3 weeks later 20/30 blob not as dark, many little specs Is having trouble reading and working on computer Dilated with 2.5% neo Evaluated with Superfield 90, BIO, Optos Diagnosed with vitreous floaters RTC 1 mo 61 y/o White Male Pt calls office 2 weeks later says vision is getting worse Referred to retinal specialist (2 weeks since last exam) Diagnosed with macula-off RD Surgery including ultimately, MP for ERM, CE/IOL 13
14 PVD 65% of individuals > 65 have PVD More common in women More common following intraocular surgery More common following inflammation More common in aphakes PVD Retinal tears occur 8-15% of eyes with symptomatic PVD 90% are superior VH occurs in 13-19% of symptomatic PVD s VH + PVD -> 70% will have a retinal break PVD No VH -> 2-4% will have retinal break Exam of a Pt with Symptomatic PVD Should have a high suspicion of detecting Weis ring Should have a high index of suspicion of a possible retinal break Clinical exam should be conducted with these suspicions Clinical Exam of a Patient with A Symptomatic PVD All the testing and procedures that you would normally do with any patient Dilated fundus exam Look specifically at the anterior vitreous Note presence or absence of pigment or cells in the anterior vitreous -> tobacco dust, schafer s sign Peripheral extended ophthalmoscopy including scleral depression Symptoms of Flashes PVD NOT Seen What is your management? Return with in 3-4 weeks Symptoms of Flashes PVD is Seen What is your management? Do you bring him back for follow up? 14
15 Management of Acute PVD With Symptoms Educate about the Si/Sx of RD Return in 4-6 weeks, then 3-4 months, then annually Lattice Degeneration as a Routine Finding? Is this any cause for concern? How do you manage it? 26 y/o Black Female Lattice Degeneration Present 5-20% of the general population Localized area of retinal thinning associated with a fluid pocket in the overlying cortical vitreous Wants to know if her astigmatism has changed? Lattice Degeneration and Risk of RD Indications for Prophylactic Treatment of Peripheral Retinal Tears and Holes in Symptomatic Patients RD develop in 0.7% of eyes with lattice degeneration followed for 10.8 yrs Eyes with lattice that developed tractional retinal tears 40% occurred in areas not associated with lattice normal-appearing retina Horseshoe tears Operculated holes Atrophic holes Treat Yes Rarely No Byer NE. Ophthalmology. 1989; 96:
16 Indications for Prophylactic Treatment of Peripheral Retinal Tears and Holes in Asymptomatic Patients Phakic Highly Myopic Fellow Eye (RD in other) Atrophic Holes No No Rarely Operculated Holes Lattice with or without Holes No Rarely Rarely No Rarely Sometimes Flap Tears Sometimes Sometimes Usually 48 y/o Asymptomatic Pilot VA 20/15 OU Anterior Segment: Unremarkable Fundus 48 y/o Pilot No Sx VA 20/15 OU Anterior Segment: Unremarkable Fundus 44 y/o Hisp Female 20/20 44 y/o Hisp Female What is Correct Diagnosis? 1. Choroidal nevus 2. Choroidal melanoma 3. Melanocytoma 4. I don t really care, I am going to refer it regardless of what the diagnosis is? 16
17 Growth over 7 ½ months < 3 mm elevation < 3 DD in size 95% are less than 2 DD Slate gray Drusen SRF associated with drusen CNVM Choroidal Nevi Features Suggesting Nevi Drusen Overlying neurosensory detachment Choroidal neovascular membrane Circinate exudate Bony pigment spiculing Zones of RPE atrophy Choroidal Melanoma >3 mm elevation Variable pigment Multiple areas of orange pigment (lipofuscin) Serous fluid (detachment) in absence of drusen Unequivocal evidence of growth 37 y/o Middle Eastern American Radiologist Presented on Monday for a refraction Blurry vision OU RE: 20/50 LE: 20/20 17
18 18
The Age-Related Eye Disease Study
What have the Age-Related Eye Disease Study (AREDS) and AREDS2 Taught Us? Emily Y. Chew, MD National Eye Institute/National Institutes of Health On Behalf of the AREDS and AREDS2 Research Groups Presenter
More informationMark Dunbar: Disclosure
Important Things to Understand About OCT Mark T. Dunbar, O.D., F.A.A.O. Bascom Palmer Eye Institute University of Miami, School of Medicine Mark Dunbar: Disclosure Optometry Advisory Board for: Allergan
More informationDiabetic Retinopatathy
Diabetic Retinopatathy Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Arctic DX Macula Risk Advanced
More informationOCT Interpretation in Retinal Disease
OCT Interpretation in Retinal Disease Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Advanced Ocular
More informationRETINA REVEALED. Dynamic Developments in AMD Diagnosis and Treatment (2014) The Dawn of: Pharmaco-Genetics (aka Nutrigenomics) Jerome Sherman, OD
RETINA REVEALED Dynamic Developments in AMD Diagnosis and Treatment (2014) The Dawn of: Pharmaco-Genetics (aka Nutrigenomics) Jerome Sherman, OD Disclosures: Jerome Sherman Dr. Sherman has lectured, received
More informationOCT Interpretation. Financial Disclosure. Jay M. Haynie, OD, FAAO. OCT Image Layers 7/21/2014
OCT Interpretation Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Olympia Tacoma Renton Kennewick - Washington Carl Zeiss
More informationLong-term Management of AMD. Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan
Long-term Management of AMD Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan DEFINITION 1 Age-related macular degeneration (AMD) is a disorder of the macula characterized
More informationFROM OUTDATED TO UPDATED Eminence-Based Medicine
FROM OUTDATED TO UPDATED Eminence-Based Medicine Evidence-Based Medicine A REVIEW OF KEY CLINICAL TRIALS Anthony DeWilde, OD FAAO 1 EMINENCE BASED MEDICINE 2 EVIDENCE BASED MEDICINE 3 4 CLINICAL TRIALS
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More informationOCT Angiography The Next Frontier
Choroid Retina avascular 5/13/2017 OCT Angiography The Next Frontier Pierce Kenworthy OD, FAAO June 9, 2017 OCT Angiography (OCTA) 2016 Non-invasive, motion contrast imaging Represents erythrocyte movement
More informationRetinal Diseases. Age-Related Macular Degeneration. What Is AMD? Risk Factors for AMD
Santosh C. Patel, M.D. Retina Specialists The Latest And Greatest in the Management of Retinal Diseases February 13, 2007 Retinal Diseases Majority of Blindness in Civilized World AMD Diabetic Retinopathy
More informationThe Age Related Eye Disease Study
The Age Related Eye Disease Study Fatoumata Yanoga, MD Assistant Professor of Ophthalmology Ohio State University Wexner Medical Center 04/13/2018 No Relevant Financial Relationships with Commercial Interests
More informationOCT Angiography in Primary Eye Care
OCT Angiography in Primary Eye Care An Image Interpretation Primer Julie Rodman, OD, MS, FAAO and Nadia Waheed, MD, MPH Table of Contents Diabetic Retinopathy 3-6 Choroidal Neovascularization 7-9 Central
More informationOphthalmology: Questions and Answers. Current Topics in Ophthalmology. Disclosures: Common Questions:
Current Topics in Ophthalmology Ophthalmology: Questions and Answers Jacque Duncan, MD Professor, Clinical Ophthalmology UCSF Primary Care Medicine: Principles and Practice October 30, 2013 With help from:
More informationClinical Trials Related to Age Related Macular Degeneration
Clinical Trials Related to Age Related Macular Degeneration Kirti Singh MD, DNB, FRCS Kirti Singh MD, DNB, FRCS, Pooja Jain MBBS, Nitasha Ahir MBBS, Divya Jain MD, DNB Guru Nanak Eye Centre, Maulana Azad
More informationRetinal Disease: What the Periphery Holds Jeffry D. Gerson, O.D., F.A.A.O.
Retinal Disease: What the Periphery Holds Jeffry D. Gerson, O.D., F.A.A.O. jgerson@hotmail.com Disclosure I have been on advisory boards/a consultant to/received honoraria from/ or been on speakers bureau
More information5/19/2015 PARDON THE OBJECTION: RETINA INTRODUCTION DISCLOSURES FERRUCCI, DUNBAR, HAYNIE, SEMES
PARDON THE OBJECTION: RETINA FERRUCCI, DUNBAR, HAYNIE, SEMES INTRODUCTION FERRUCCI: Chief, Optometry, Sepulveda VA; Professor, MBKU/SCCO DUNBAR: Optometric Director, Bascom Palmer Eye Institute and University
More informationDiabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina
Diabetic Retinopathy: Managing the Extremes J. Michael Jumper, MD West Coast Retina Case 1: EC 65 y.o. HM No vision complaints Meds: Glyburide Metformin Pioglitazone Va: 20/20 OU 20/20 Case 2: HS 68 y.o.
More informationZEISS AngioPlex OCT Angiography Overview ZEISS OCT Angiography
ZEISS AngioPlex OCT Angiography Overview ZEISS OCT Angiography California, ZEISS AngioPlex Ultra-clear visualization of microvascular blood flow using non-invasive OCT angiography 2 AngioPlex OCT Angiography
More informationOptical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D.
Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D. Disclosure OCT Optical Coherence Tomography No relevant financial relationships I will refer to
More informationDr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre
Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre 11:00-11:55 WS #115: The Revolution in Macular Degeneration Management 12:05-13:00 WS #127: The Revolution in Macular
More informationPosterior Segment Disease: Case Challenges
Disclosures Posterior Segment Disease: Case Challenges Steven Ferrucci, OD, FAAO Chief, Optometry Sepulveda VA Professor, SCCO/MBKU Speakers bureau and/or Advisory Board for: Alcon Allergan Macula Risk
More information1/25/2018. Case Management Strategies in Diabetic Retinopathy. Case Study #1: Severe DME. DDOS: 3/31/2016 Va 20/400. Disclosures
Case Management Strategies in Diabetic Retinopathy Disclosures No financial conflict of interest Will discuss off label use of intraocular Bevacizumab (Avastin) for Diabetic Retinopathy Sundeep Dev, MD
More informationDisclosures. Objectives 1/28/2019. None. To review a selection of retina journal publications from 2018 that have broad clinical relevance
Disclosures 2018 Retina Articles You Should Know A few retina articles from 2018 that I liked and you might find interesting None D. Wilkin Parke III, M.D. VitreoRetinal Surgery, PA 1 2 Objectives To review
More informationIncorporating OCT Angiography Into Patient Care
Incorporating OCT Angiography Into Patient Care Beth A. Steele, OD, FAAO OCT A: Introduction Isolates microvascular circulation from OCT image data Axial resolution = 5 microns (i.e. fine capillaries visible)
More informationADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY. By: Chris Munnerlyn, OMT Student University of Arkansas for Medical Sciences
ADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY By: Chris Munnerlyn, OMT Student University of Arkansas for Medical Sciences ADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY (AOFVD) AOFVD is a condition that
More informationZEISS AngioPlex OCT Angiography. Clinical Case Reports
Clinical Case Reports Proliferative Diabetic Retinopathy (PDR) Case Report 969 PROLIFERATIVE DIABETIC RETINOPATHY 1 1-year-old diabetic female presents for follow-up of proliferative diabetic retinopathy
More informationCourse # Getting to Know Your OCT
Course # 140 Getting to Know Your OCT Course Title: Lecturer: Getting to Know Your OCT Brad Sutton, OD, FAAO IU School of Optometry Financial Disclosures No financial disclosures Optical Coherence Tomography-OCT
More informationRetinal Complications of Obstructive Sleep Apnea A Growing Concern!
Retinal Complications of Obstructive Sleep Apnea A Growing Concern! Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationPast ocular history. DME Case 1. Patient presents blurred VA. Hemoglobin A1c 11.5% -- patient states sugars have not been in good control
Past ocular history Patient presents blurred VA DME Case 1 Hemoglobin A1c 11.5% -- patient states sugars have not been in good control PDR with macular edema OU Rishi Singh MD Cleveland Clinic OD OS 1
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May
BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of
More informationPrevention and treatment of agerelated macular degeneration
THERAPY REVIEW Prevention and treatment of agerelated macular degeneration SARAH HORTON AND CATHERINE GULY Age-related macular degeneration (AMD) is a common cause of visual loss in older people and GPs
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationInnovations in Retina:
Innovations in Retina: Impressions From a Blue Collar Lunch Pail Optometrist Mark T. Dunbar, O.D., F.A.A.O. Bascom Palmer Eye Institute University of Miami, Miller School of Medicine Miami, FL Disclosures
More information25% of normal 2/20/2018. Practical Guidelines for the Treatment of AMD 78% 22% Overview. AMD Information Overload
I am a consultant / or have financial interest in: Practical Guidelines for the Treatment of Maculogix J&J Acuvue Vision Source Ocusoft Pogo Tech Jeffrey W. Jones, OD Longview, TX 75605 jjoneseye@gmail.com
More information04/11/2014. Retina Coding and Reimbursement 101. Financial Disclosure. Chief Complaint
Retina Coding and Reimbursement 101 William T. Koch, COA, COE, CPC Administrative Director Director of Billing Operations The Retina Institute St. Louis, Missouri Advisory Boards Allergan Genentech Regeneron
More informationProgressive Symptomatic Retinal Detachment Complicating Retinoschisis. Initial Reporting Questionnaire
Progressive Symptomatic Retinal Detachment Complicating Retinoschisis In association with the British Ophthalmological Surveillance Unit Ethics ref: 13/NW/0037 Initial Reporting Questionnaire Case Definition:
More informationPosterior Segment Disease: Case Challenges
CHRPE Posterior Segment Disease: Case Challenges Steven Ferrucci, OD, FAAO Chief, Optometry Sepulveda VA Professor, SCCO/MBKU! Lesions are almost always stable in size, but color may change. Very rare
More informationBilling Requirements for Intravitreal Injections. Financial Interest. Indications. Documentation. Documentation. Documentation
Billing Requirements for Intravitreal Injections Financial Interest ASCRS ASOA Symposium & Congress Practice Management Program Los Angeles, California May 5-9, 2017 Presented by: Patricia Kennedy, COMT,
More informationPatient AB. Born in 1961 PED
Clinical Atlas Patient AB Born in 1961 PED Autofluorescence Dilated 45 EasyScan Zero-dilation IR 45 Fundus Dilated 45 In the fundus photos (Canon CX1) the PED is not able to be seen. However, the extent
More informationDiabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches
Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada
More informationFundus Autofluorescence. Jonathan A. Micieli, MD Valérie Biousse, MD
Fundus Autofluorescence Jonathan A. Micieli, MD Valérie Biousse, MD The retinal pigment epithelium (RPE) has many important functions including phagocytosis of the photoreceptor outer segments Cone Rod
More informationABCs. ABCs of retinal disease !"#$"%!& Disclosures. ABCs three major threats to vision where 1 o care intervention may be helpful!a = AMD !
Disclosures Stockholder: HPO ABCs of retinal disease Honoraria, Consultant or Advisory Board: Alcon, Allergan, B&L, Arctic Dx, Sucampo, Zeiss. Idaho Optometric Physicians 2016 Leo Semes, OD, FAAO ABCs
More informationAge-Related Eye Diseases and Conditions. Jonathan M. Frantz, MD, F.A.C.S. Cataract and Refractive Surgeon
Age-Related Eye Diseases and Conditions Jonathan M. Frantz, MD, F.A.C.S. Cataract and Refractive Surgeon Vision Changes Patients notice vision changes with aging. Many changes are common and can often
More informationOptical Coherence Tomography in Diabetic Retinopathy. Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP
Optical Coherence Tomography in Diabetic Retinopathy Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP Content OCT imaging Retinal layers OCT features in Diabetes Some NON DR features
More informationFront Line Diabetic Retinopathy What Not to Miss and Why
Front Line Diabetic Retinopathy What Not to Miss and Why David M Brown MD FACS Clinical Professor of Ophthalmology Blanton Eye Institute, Houston Methodist Hospital Baylor College of Medicine Retina Consultants
More informationJay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington
Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington I Jay M. Haynie, OD, FAAO have received honoraria from the following companies: Reichert Technologies Notal Vision Carl Zeiss Meditec
More information04/06/2015. Documentation Do s and Don ts In The Retina Practice. Financial Disclosure. Documentation Dos and Don ts
Documentation Do s and Don ts In The Retina Practice William T. Koch, COA, COE, CPC Administrative Director Director of Billing Operations The Retina Institute St. Louis, Missouri Advisory Boards Allergan
More informationA(REDS) to Z(inc) Nutrition for eye health
All eyes on the macula A(REDS) to Z(inc) Nutrition for eye health Professor Christine Purslow PhD, MCOptom, FBCLA, FIACLE Macula lutea = yellow spot Colour is determined by 3 carotenoids Lutein Zeaxanthin
More informationPosterior Segment Update
Posterior Segment Update Featured Speaker: Dr. Kyle Cheatham, FAAO, DIP ABO DISCLOSURE STATEMENT We have no direct financial or proprietary interest in any companies, products or services mentioned in
More informationTop Pediatric Retinal Diseases you don t want to miss! Retinopathy of Prematurity (ROP) Aggressive, Posterior ROP (AP ROP)
Top 10 10 Pediatric Retinal Diseases you don t want to miss! Polly Quiram MD, PhD Vitreoretinal Surgery, PA Retinal Update Jan 26th, 2018 ROP Retinoblastoma Coats disease Persistent fetal vasculature Familial
More informationInteresting, unusual and eclectic cases from 2017 Robert A. Mittra, MD VitreoRetinal Surgery, P.A. Minneapolis, MN
Fundus, SG Interesting, unusual and eclectic cases from 2017 Robert A. Mittra, MD VitreoRetinal Surgery, P.A. Minneapolis, MN Which is most likely? A) Age > 65, history of HTN B) Age 40 65, history of
More informationPART 1: GENERAL RETINAL ANATOMY
PART 1: GENERAL RETINAL ANATOMY General Anatomy At Ora Serrata At Optic Nerve Head Fundoscopic View Of Normal Retina What Is So Special About Diabetic Retinopathy? The WHO definition of blindness is
More informationAGE RELATED MACULAR DEGENERATION (AMD) PREFERRED PRACTICE PATTERNS (PPP) Philippines: 2016
AGE RELATED MACULAR DEGENERATION (AMD) PREFERRED PRACTICE PATTERNS (PPP) Philippines: 2016 The Age Related Macular Degeneration (AMD) Preferred Practice Patterns (PPP) Philippines: 2016 was prepared by
More informationEyes on Diabetics: How to Avoid Blindness in Diabetic Patient
Eyes on Diabetics: How to Avoid Blindness in Diabetic Patient Rova Virgana FK Unpad Pusat Mata Nasional RS Mata Cicendo Bandung Eye Center (Hospital and Clinic) PIT IDI Jabar 2018 Keys Facts from WHO
More informationInteresting, unusual, eclectic cases from 2017 Robert A. Mittra, MD VitreoRetinal Surgery, P.A. Minneapolis, MN
56 yo female, EW Presented to outside Ophthalmologist Diagnosed with viral conjunctivitis, but viral testing was negative. Also had pain around the eye and on the right side of her face Interesting, unusual,
More informationIntraocular Radiation Therapy for Age-Related Macular Degeneration
Medical Policy Manual Medicine, Policy No. 134 Intraocular Radiation Therapy for Age-Related Macular Degeneration Next Review: April 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER
More informationObjective Assessment of Macula and Optic Nerve
Objective Assessment of Macula and Optic Nerve Jerry Sherman Disclosure: Dr. Sherman has lectured and received honorarium from Carl Zeiss Meditec, Topcon, Optovue, Optos, and PHP, Diopsys, Eye Solutions,Quantel,
More informationRoyal Berkshire Hospital Dunedin Hospital. Prince Charles Eye Unit Pi Princess Margaret Hospital
Vitreoretinal Surgery Mr Vaughan Tanner www.tanner-eyes.co.uk eyes Reading Royal Berkshire Hospital Dunedin Hospital Windsor Prince Charles Eye Unit Pi Princess Margaret Hospital Success rates VR surgery
More informationPrinciple of OCT. Reading Between the Lines: OCT Interpretation. Initial Concept. Advantage: High Resolution Cross Section Images
Principle of OCT Reading Between the Lines: OCT Interpretation Mohammad Rafieetary, OD, FAAO mrafieetary@charlesretina.com Introduction Optical Biopsy Morphologic Evaluation of Live Tissue Measurements
More informationThe Human Eye. Cornea Iris. Pupil. Lens. Retina
The Retina Thin layer of light-sensitive tissue at the back of the eye (the film of the camera). Light rays are focused on the retina then transmitted to the brain. The macula is the very small area in
More informationBrampton Hurontario Street Brampton, ON L6Y 0P6
Diabetic Retinopathy What is Diabetic Retinopathy Diabetic retinopathy is one of the leading causes of blindness world-wide. Diabetes damages blood vessels in many organs of the body including the eyes.
More informationMeasures have been taken, by the Utah Department of Health, Bureau of Health Promotions, to ensure no conflict of interest in this activity.
Measures have been taken, by the Utah Department of Health, Bureau of Health Promotions, to ensure no conflict of interest in this activity. CNE/CPE/CEU s are available for this live webinar. You must
More informationVITREOMACULAR UPDATE FOR THE PRIMARY CARE OD
VITREOMACULAR UPDATE FOR THE PRIMARY CARE OD VITREOMACULAR UPDATE FOR THE PRIMARY CARE OD 1 2 DISCLOSURE STATEMENT I have received lecture honoraria from TearScience. I have no direct financial or proprietary
More informationFacts About Diabetic Eye Disease
Facts About Diabetic Eye Disease Points to Remember 1. Diabetic eye disease comprises a group of eye conditions that affect people with diabetes. These conditions include diabetic retinopathy, diabetic
More informationDiabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? WHAT CAUSES DIABETIC RETINOPATHY? WHAT ARE THE STAGES OF DIABETIC RETINOPATHY?
Diabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? Diabetic retinopathy affects 8 million Americans with diabetes. A leading cause of blindness in American adults, it is caused by damage to the small blood
More informationOCT Angiography. SriniVas Sadda, MD
OCT Angiography SriniVas Sadda, MD Professor of Ophthalmology Director, Medical Retina Unit Ophthalmic Imaging Unit University of Southern California Los Angeles, California, USA Disclosure Consulting
More informationevaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography
evaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography Dr. Mahmoud Alaa Abouhusssein, FRCO Lecturer of ophthalmology, Alexandria university Dr. Amir Ramadan Gomaa, MD
More informationTreatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity
Diabetic Retinopathy Clinical Research Network Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity Version 3.0 April 18, 2014 Treatment of CIDME in Eyes with Good
More informationOverview of the Pathogenesis of Diabetic Retinopathy
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationUpdate on Retina. Gokul Kumar, MD Central Florida Retina October 1, 2017
Update on Retina Gokul Kumar, MD Central Florida Retina October 1, 2017 Overview Part 1: The Changing Landscape of Central Serous Chorioretinopathy and Related Disorders CSR, Pachychoroid Disease Spectrum
More information11/29/2016 MACULAR MALADIES: TYPICAL & ATYPICAL CASES
MACULAR MALADIES: TYPICAL & ATYPICAL CASES Dawn Pewitt, OD, FAAO Triad Eye Institute, Grove, OK Dpewitt@triadeye.com Disclosure Statement: No financial disclosures COPE 51218-PS Please silence all mobile
More informationThe Quick Guide to OCT Mastery 50 Real Cases with Expert Analysis
OPTICAL COHERENCE TOMOGRAPHY The Quick Guide to OCT Mastery 50 Real Cases with Expert Analysis VOL 1 Sanjay Sharma, MD, FRCS, MSc (Epid), MBA Ophthalmologist, Epidemiologist Queen s University, Canada
More informationOutline. Outline. Vitreous Development & Anatomy OPT - 243
2010 OPT - 243 Vitreous Disorders & Vitreoretinal Disorders of the Posterior Pole I Leo Semes, OD, FAAO 100% 0% 0% 0% 0% Which of these gives the best resolution for studying vitreoretinal disorders of
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #14 (NQF 0087): Age-Related Macular Degeneration (AMD): Dilated Macular Examination National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More information10/17/2017. FDA Approved. Zeiss AngioPlex TM Optovue AngioVue TM
Images retinal microvasculature without dye injection Displays structure and function from a single imaging system Standard of Care-2011 DFE, Fundus Photos, VF 10-2, SD-OCT, FAF, or mferg 2016-AAO Baseline
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
More informationOphthalmology Macular Pathways
Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological
More informationWill OCT-Angiography replace FA?
ASL Roma A PRESIDIO TERRITORIALE NUOVO REGINA MARGHERITA AMBULATORIO PATOLOGIE RETINICHE Resp. Dott.ssa SUSANNA CATALANO CENTRO ITALIANO MACULA Will OCT-Angiography replace FA? Marco Rispoli, Luca di Antonio,
More informationApplications of Sustained Release Delivery Systems in Ocular Disease
Applications of Sustained Release Delivery Systems in Ocular Disease Formulation and Delivery Systems For Peptide and Protein 2012 December 5, 2012 Christopher A. Rhodes, Ph.D. Principal, Christopher A
More information8/6/17. Disclosures Aerie Pharmaceuticals Alcon BioTissue Diopsys Optovue Shire
Nathan Lighthizer, O.D., F.A.A.O. Associate Professor Assistant Dean for Clinical Care Director of Continuing Education Chief of Specialty Care Clinics Oklahoma College of Optometry Tahlequah, OK lighthiz@nsuok.edu
More informationFinancial Disclosures
Financial Disclosures Consultant Genentech, Regeneron, Allergan, Thrombogenics, Optos, and ArcticDx Grant Support Regeneron, Allergan Mathew W. MacCumber, MD, PhD Professor & Assoc. Chair for Research
More informationOptical Coherence Tomograpic Features in Idiopathic Retinitis, Vasculitis, Aneurysms and Neuroretinitis (IRVAN)
Columbia International Publishing Journal of Ophthalmic Research (2014) Research Article Optical Coherence Tomograpic Features in Idiopathic Retinitis, Vasculitis, Aneurysms and Neuroretinitis (IRVAN)
More informationIntroduction. Pardon the Objection: Posterior Segment Update. Disclosures. Introduction. Steven Ferrucci, OD, FAAO 5/23/2014. Fast paced! Interactive!
Introduction Pardon the Objection: Posterior Segment Update Steven Ferrucci, OD, FAAO Mark Dunbar, OD, FAAO Maynard Pohl, OD, FAAO Diana Shechtman, OD, FAAO Fast paced! Interactive! Panel participation!
More informationPractical Care of the Cataract Patient with Retinal Disease
Practical Care of the Cataract Patient with Retinal Disease Brooks R. Alldredge, OD, FAAO Kelly L. Cyr, OD, FAAO The Retina Center Eye Associates of New Mexico 4411 The 25 Way NE, Suite 325 Albuquerque,
More informationDiabetic Macular Edema Treatment in the 21st Century
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (Protocol
More informationACTIVATED OR NOT? RETINAL CASE PRESENTATION Shorye Payne, MD Medical Retinal Specialist Robley Rex VA Eye Clinic
ACTIVATED OR NOT? RETINAL CASE PRESENTATION Shorye Payne, MD Medical Retinal Specialist Robley Rex VA Eye Clinic C We anticipate that the future management of posterior uveal melanoma (PUM) will focus
More informationThe Foundation WHAT IS THE RETINA?
Age-Related Macular Degeneration (AMD) is a deterioration of the retina and choroid that leads to a substantial loss in visual acuity (sharpness of vision). AMD is the leading cause of significant visual
More information! Reichert, Alcon, Allergan, CZ & Zeavision. Uchino, E. et al. Arch Ophthalmol ! Vitreoschisis (split within the vitreous)! ERM!
Financial disclosure From Print to Practice: PVD a common process with potential for ocular morbidity! I have received lecture honoraria or serve on the advisory boards or speaker s bureaus of:! Reichert,
More informationRetina Conference. Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014
Retina Conference Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014 Subjective CC/HPI: 64 year old Caucasian female referred by outside ophthalmologist
More informationDownloaded from:
Evans, JR; Lawrenson, JG (2013) Dietary interventions for AMD: what do we know and what do we not know? The British journal of ophthalmology. ISSN 0007-1161 DOI: https://doi.org/10.1136/bjophthalmol- 2013-303134
More informationFood, Supplements and Healthy Lifestyles in Slowing and Preventing Macular Degeneration Julie Mares, Professor For the Nutrition and Eye Health Research Team http://nutritionforeyes.ophth.wisc.edu Preserving
More informationCommon Causes of Vision Loss
Common Causes of Vision Loss Learning Objectives To identify the most common causes of vision loss in the United States To differentiate the most common forms of agerelated macular degeneration and diabetic
More informationRETINA 2018 OBJECTIVES OCT VERY USEFUL INFORMATION SAFE AND FRIENDLY 1/11/2018 KELLY MITCHELL
RETINA 2018 KELLY MITCHELL OBJECTIVES HIGHLIGHT NEW DIAGNOSTIC & TREATMENT OPTIONS REVIEW DIAGNOSTIC KEYS OF SELECT RETINAL DISEASES DISCUSS USE OF IMAGING AND REFERRAL RECOURSES FOR PATIENT BENEFIT OCT
More informationOCT Assessment of the Vitreoretinal Relationship in CSME
December 2007 Sonia Rani John et al. - IFIS 375 ORIGINAL ARTICLE OCT Assessment of the Vitreoretinal Relationship in CSME Dr. Manoj S. DNB FRCS, Dr. Unnikrishnan Nair MS DO FRCS, Dr. Gargi Sathish MS Introduction
More informationRecalcitrant Diabetic Macular Oedema: Therapeutic Options
December 2007 A. Giridhar et al. - Recalcitrant DME 451 CONSULTATION S E C T I O N Recalcitrant Diabetic Macular Oedema: Therapeutic Options Dr. Cyrus M Shroff 1, Dr. N S Muralidhar 2, Dr. R Narayanan
More informationOptometry Student Extern Manual. Miami VA Medical Center
Optometry Student Extern Manual Miami VA Medical Center Table of contents: Rotation Description 3 Clinic Schedules 4 Absences 4 Performance Standards 5 When to check in with attending 5 References 6 Visual
More informationDiabetic eye disease. Diabetic retinopathy. Sam S. Dahr, M.D. Retina Center of Oklahoma.
Diabetic eye disease Sam S. Dahr, M.D. Retina Center of Oklahoma www.rcoklahoma.com Downloaded from: The Retina (on 28 May 2007 12:48 AM) 2007 Elsevier Diabetic retinopathy Downloaded from: The Retina
More information